Adenomyosis – CMA Clinical Spotlight – Dr Amrita Singh
Adenomyosis is a benign gynaecological condition in which tissue similar to the lining of the uterus (endometrial tissue) grows into the muscular wall of the uterus (myometrium). This causes the uterine muscle to become thickened and enlarged, often leading to painful and heavy menstrual periods (NHS, 2023).
In adenomyosis, the displaced endometrial tissue continues to behave as it normally would during the menstrual cycle—thickening, breaking down, and bleeding. However, because this tissue is trapped within the uterine muscle, it can lead to inflammation, uterine enlargement, and increased menstrual pain (Mayo Clinic, 2018).
The condition most commonly affects people in their 30s and 40s, particularly those who have had previous pregnancies or uterine surgery, although it can occur at any reproductive age (Cleveland Clinic, 2023). In some individuals, adenomyosis may cause significant symptoms, while others may remain asymptomatic and only be diagnosed incidentally during imaging or surgery (NHS, 2023).
Although adenomyosis is a chronic condition, it is not cancerous and does not increase the risk of uterine cancer. Management focuses on symptom control, improving quality of life, and addressing associated menstrual and pelvic pain, with treatment options tailored to the individual’s age, symptoms, and reproductive goals (Mayo Clinic, 2018; Chernofsky, 2022).
Causes
The exact cause of adenomyosis is not fully understood, but several theories explain how endometrial-like tissue may come to grow within the muscular wall of the uterus (myometrium) (NHS, 2023).
One widely accepted theory is invasive tissue growth, where endometrial cells move directly into the uterine muscle from the uterine lining. This may occur following uterine trauma, such as childbirth, caesarean section, or other uterine surgery, which can disrupt the normal boundary between tissue layers (Mayo Clinic, 2018).
Another proposed mechanism involves developmental origins, suggesting that adenomyosis may begin before birth if endometrial tissue becomes embedded in the uterine muscle during foetal development and later becomes active during reproductive years (Cleveland Clinic, 2023).
Inflammation related to childbirth is also thought to play a role. Post-pregnancy inflammation of the uterine lining may allow endometrial cells to penetrate the uterine muscle more easily, which may help explain why adenomyosis is more common in individuals who have had one or more pregnancies (NHS, 2023).
Hormonal influences are considered significant, as adenomyosis is oestrogen-dependent. Symptoms often improve after menopause, when oestrogen levels decline, supporting the role of hormones in the development and persistence of the condition (Mayo Clinic, 2018).
While the precise cause remains unclear, adenomyosis is increasingly recognised as a multifactorial condition, involving a combination of hormonal, inflammatory, structural, and possibly developmental factors (Cleveland Clinic, 2023).
Symptoms
The symptoms of adenomyosis can vary widely in type and severity. Some individuals experience significant discomfort, while others may have no noticeable symptoms and are diagnosed incidentally during imaging or surgery (NHS, 2023).
One of the most common symptoms is heavy menstrual bleeding (menorrhagia), which may involve prolonged periods, passing large clots, or bleeding that interferes with daily activities. This can sometimes lead to iron-deficiency anaemia, contributing to fatigue and weakness (Chernofsky, 2022; Mayo Clinic, 2018).
Painful periods (dysmenorrhoea) are also frequently reported. Menstrual pain associated with adenomyosis is often described as deep, aching, or cramping and may worsen over time. Unlike typical period pain, it may not respond well to simple pain relief measures (Cleveland Clinic, 2023).
Many individuals experience chronic pelvic pain, which may persist outside of menstruation. Pain during or after sexual intercourse (dyspareunia) can also occur, affecting intimacy and quality of life (Mayo Clinic, 2018).
Adenomyosis can cause the uterus to become enlarged and tender, leading to sensations of pelvic pressure, bloating, or abdominal heaviness. Some people describe feeling “constantly swollen” in the lower abdomen (NHS, 2023).
In addition to physical symptoms, the ongoing nature of pain and heavy bleeding may contribute to emotional distress, low mood, anxiety, and reduced quality of life, particularly when symptoms interfere with work, relationships, or daily functioning (Chernofsky, 2022).
Types
Adenomyosis is commonly classified based on how the endometrial-like tissue is distributed within the uterine muscle. The two main recognised types are:
Diffuse adenomyosis
This is the most common form. Endometrial-like tissue is spread widely throughout the uterine muscle, causing the uterus to become enlarged, thickened, and tender. Diffuse adenomyosis is often associated with heavy menstrual bleeding, painful periods, and chronic pelvic pain (NHS, 2023; Mayo Clinic, 2018).
Focal adenomyosis (adenomyoma)
In this type, adenomyosis is localised to one area of the uterine muscle, forming a defined mass known as an adenomyoma. Symptoms may be similar to those of uterine fibroids and can include localised pain or pressure, depending on size and location (Cleveland Clinic, 2023).
Both types are benign and may coexist with other gynaecological conditions, such as fibroids or endometriosis. The type and extent of adenomyosis can influence symptom severity and guide management decisions (Mayo Clinic, 2018).
Risk factors
Adenomyosis is more likely to occur in certain individuals due to a combination of hormonal, reproductive, and uterine factors, although it can develop in anyone with a uterus (NHS, 2023).
One of the most consistently identified risk factors is age. Adenomyosis is most commonly diagnosed in people aged 30–50 years, particularly during the later reproductive years, likely due to prolonged exposure to oestrogen over time (Mayo Clinic, 2018).
A history of pregnancy and childbirth is another significant risk factor. Adenomyosis is more frequently observed in individuals who have had one or more pregnancies, possibly due to uterine changes, inflammation, or tissue disruption associated with pregnancy and delivery (NHS, 2023; Cleveland Clinic, 2023).
Previous uterine surgery increases risk. Procedures such as caesarean section, dilation and curettage (D&C), or fibroid removal may disrupt the boundary between the endometrial lining and uterine muscle, allowing endometrial tissue to grow into the myometrium (Mayo Clinic, 2018).
Hormonal exposure, particularly prolonged exposure to oestrogen, is thought to play an important role. This is supported by the observation that symptoms often improve after menopause, when oestrogen levels naturally decline (Cleveland Clinic, 2023).
Adenomyosis is also more commonly seen in individuals who have co-existing gynaecological conditions, such as endometriosis or uterine fibroids, suggesting shared risk factors or overlapping disease processes (Chernofsky, 2022).
Complications
Adenomyosis is a benign (non-cancerous) condition, but if symptoms are severe or poorly managed, it can lead to a range of physical, emotional, and quality-of-life complications (NHS, 2023).
One of the most common complications is chronic heavy menstrual bleeding, which may result in iron-deficiency anaemia. Anaemia can cause persistent fatigue, weakness, shortness of breath, and reduced ability to carry out daily activities (Chernofsky, 2022).
Chronic pelvic pain is another significant complication. Ongoing pain, whether cyclical or continuous, can interfere with work, sleep, physical activity, and intimate relationships, contributing to long-term discomfort and reduced wellbeing (Cleveland Clinic, 2023).
Adenomyosis may also have an impact on fertility, although the relationship is not fully understood. Some individuals with adenomyosis experience difficulty conceiving or maintaining a pregnancy, particularly when the condition coexists with endometriosis or uterine fibroids (Mayo Clinic, 2018).
The persistent nature of symptoms such as pain, heavy bleeding, and fatigue can lead to psychological complications, including low mood, anxiety, emotional distress, and reduced quality of life. These effects may be exacerbated when symptoms are long-standing or inadequately controlled (Chernofsky, 2022).
In more severe cases, symptoms may become refractory to medical management, leading some individuals to consider more invasive treatments, including surgical options. Decisions around treatment can be emotionally challenging, particularly for those who wish to preserve fertility (NHS, 2023).
Prognosis
The prognosis for adenomyosis is generally favourable, particularly when the condition is recognised early and managed appropriately. While adenomyosis is a chronic condition, many individuals experience meaningful symptom relief with tailored medical treatment and supportive care (NHS, 2023).
Symptoms often respond well to hormonal therapies, pain management strategies, and lifestyle adjustments, allowing many people to maintain a good quality of life. The severity of symptoms varies, and some individuals experience only mild or intermittent discomfort, while others may require ongoing management (Mayo Clinic, 2018).
A key feature of adenomyosis is its hormone-dependent nature. Symptoms typically improve or resolve after menopause, when oestrogen levels decline naturally, which contributes to a more positive long-term outlook (Cleveland Clinic, 2023).
For individuals with severe or persistent symptoms that do not respond to conservative treatment, surgical options may be considered. While such interventions can significantly improve symptoms, decisions around treatment must take into account fertility wishes and personal circumstances (NHS, 2023; Chernofsky, 2022).
Although adenomyosis can affect fertility and quality of life in some individuals, it does not increase the risk of uterine cancer. With appropriate medical support, education, and follow-up, most people with adenomyosis can expect a stable and manageable long-term prognosis (Mayo Clinic, 2018).
Nutritional perspective
Nutrition plays a supportive role in the management of adenomyosis by helping to address symptoms such as inflammation, heavy menstrual bleeding, pain, and fatigue. While dietary changes cannot cure adenomyosis or replace medical treatment, appropriate nutrition may contribute to symptom control and overall wellbeing (NHS, 2023).
Because adenomyosis is associated with heavy menstrual bleeding, maintaining adequate iron intake is important to reduce the risk of iron-deficiency anaemia. Iron-rich foods such as leafy green vegetables, legumes, pulses, nuts, seeds, and iron-fortified foods may be beneficial, alongside medical advice where supplementation is required (Chernofsky, 2022).
Adenomyosis is considered an oestrogen-dependent and inflammatory condition, so dietary patterns that support inflammation regulation may be helpful. Diets rich in fruits, vegetables, whole grains, healthy fats (such as omega-3 fatty acids), and minimally processed foods may support general inflammatory balance and menstrual health (Mayo Clinic, 2018).
Maintaining stable blood sugar levels through regular, balanced meals can also help support energy levels and reduce fatigue, particularly in individuals experiencing chronic pain or blood loss. Skipping meals or relying heavily on ultra-processed foods may exacerbate tiredness and discomfort (NHS, 2023).
Long-term pain or hormonal treatment may affect bone and general health, so ensuring adequate intake of calcium, vitamin D, and protein supports overall physical resilience and wellbeing (Cleveland Clinic, 2023).
Nutritional strategies for adenomyosis should always be individualised, taking into account symptom severity, treatment plan, and personal health needs, and should complement—not replace—medical management (NHS, 2023; Mayo Clinic, 2018).
Psychological perspective
Adenomyosis can have a significant psychological and emotional impact, particularly due to its chronic nature and the burden of ongoing symptoms such as pain, heavy bleeding, and fatigue. These physical symptoms can affect emotional wellbeing, stress levels, and overall quality of life (NHS, 2023).
Many individuals with adenomyosis report low mood, anxiety, irritability, and emotional exhaustion, especially when symptoms are persistent or unpredictable. Chronic pelvic pain and heavy menstrual bleeding may interfere with work, social activities, and relationships, contributing to feelings of frustration, helplessness, or reduced self-esteem (Cleveland Clinic, 2023).
The condition may also place strain on intimate relationships and sexual wellbeing, particularly when pain during intercourse (dyspareunia) is present. This can lead to avoidance, guilt, or emotional distance, further affecting psychological health (Mayo Clinic, 2018).
Delays in diagnosis or feeling that symptoms are minimised can increase psychological distress, with some individuals feeling unheard or misunderstood within healthcare settings. This may heighten stress and reduce confidence in seeking help (Chernofsky, 2022).
Psychological wellbeing often improves when adenomyosis is acknowledged, clearly explained, and appropriately managed. Access to supportive care, clear information, stress-management strategies, and—where needed—psychological support can help individuals cope more effectively with the condition and improve overall quality of life (NHS, 2023; Chernofsky, 2022).
Homeopathic perspective
From a homeopathic perspective, adenomyosis is understood as a chronic constitutional condition, reflecting deeper hormonal, inflammatory, and emotional imbalances within the individual rather than a localised uterine disorder alone. Homeopathy approaches adenomyosis by focusing on the person as a whole, taking into account physical symptoms, menstrual patterns, emotional wellbeing, stress responses, and overall vitality.
In practice, homeopathic treatment is highly individualised. Two individuals with adenomyosis may experience very different symptom patterns—such as variations in pain intensity, bleeding characteristics, emotional responses, and stress tolerance—and these differences guide remedy selection rather than the diagnosis alone. Attention is often given to factors such as menstrual regularity, pain modalities, fatigue, mood changes, and the impact of stress or hormonal fluctuations.
Living with a chronic gynaecological condition can place a significant emotional and psychological burden on individuals. From a complementary perspective, homeopathic support may be sought to help individuals cope with chronic pain, emotional strain, hormonal transitions, and reduced quality of life, while recognising that symptom monitoring remain essential.
When used responsibly, a complementary homeopathic approach may focus on supporting overall wellbeing, stress adaptation, and resilience, while respecting clinical boundaries and prioritising patient safety within an integrated care framework.
Summary
Adenomyosis is a benign, chronic gynaecological condition in which endometrial-like tissue grows into the muscular wall of the uterus, often leading to heavy menstrual bleeding, painful periods, pelvic pain, and fatigue. While some individuals remain asymptomatic, others experience symptoms that can significantly affect daily functioning and quality of life.
The condition is most commonly diagnosed in people aged 30–50 years and is influenced by hormonal, reproductive, and uterine factors. Although the exact cause is not fully understood, adenomyosis is recognised as an oestrogen-dependent condition, with symptoms often improving after menopause.
With appropriate medical management, education, and supportive care, the prognosis is generally favourable. Nutritional, psychological, and carefully managed complementary approaches may help support wellbeing when used alongside conventional medical care, but they should never replace medical assessment or treatment.
Early recognition, clear explanation, and an integrated, person-centred approach are central to improving outcomes and supporting individuals living with adenomyosis.
References
Cleveland Clinic. (2023, January 30). Adenomyosis: Symptoms, Causes, Tests and Treatments. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/14167-adenomyosis
Mayo Clinic. (2018). Adenomyosis – Symptoms and causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/adenomyosis/symptoms-causes/syc-20369138
Chernofsky, M. (2022, June 30). Adenomyosis. Www.hopkinsmedicine.org. https://www.hopkinsmedicine.org/health/conditions-and-diseases/adenomyosis
NHS. (2023, July 21). Adenomyosis. Nhs.uk. https://www.nhs.uk/conditions/adenomyosis/
For further CMA clinical insights, please visit our Conditions pages here.
CMA CPD Reflective Practice Questions (1 Hour CPD)
Reflective practice helps you translate clinical knowledge into safe, compassionate, and effective client care. After reading this article on adenomyosis, please take a few moments to reflect on the following questions and record your responses for your CMA CPD records.
1. Clinical awareness
What were your key learning points from this article? Did any of the symptoms, risk factors, or complications increase your awareness of issues you may encounter in practice?
2. Professional scope and safety
How confident do you feel in recognising when a client presenting with symptoms such as heavy menstrual bleeding, fatigue, or pelvic pain may need referral to a GP or specialist? How would you approach this conversation sensitively?
3. Whole-person support
Adenomyosis can affect physical, emotional, and psychological wellbeing. How might you support a client living with a chronic gynaecological condition within the boundaries of your professional role?
4. Practice integration
Has this article highlighted any areas where you would like to expand your knowledge or skills in women’s health? What steps could you take to strengthen your professional competence in this area?
5. Reflection and action
What is one specific insight from this article that you will carry forward into your professional practice?
CPD Reflection Record
Please write a short reflective summary (150–300 words) outlining what you have learned and how it may influence your professional awareness or client support.
This reflection may be counted towards your annual CMA Continuing Professional Development requirement. The best way to do this is to respond to the questions above and then either photograph or print and scan your responses and upload them to your CMA/CPD section in your membership space or here on the CMA website.
About the Author
Amrita Singh is a qualified Homoeopath, Psychologist, and Nutritionist with a strong multidisciplinary foundation in mind–body health. She holds an MSc in Psychology (UK) and an MSc in Food, Nutrition & Dietetics (India), alongside formal training in classical homoeopathy from the Central College of Homoeopathy, London. She is currently pursuing postgraduate studies with the Irish School of Homoeopathy.
A full member of the Complementary Medical Association (MCMA), Homoeopathy International (R. Hom. Int.), the British Psychological Society (Graduate Member), and Balen’s insured, Amrita integrates emotional insight, nutritional balance, and gentle homoeopathic care in her clinical approach.
Formerly the Head of Department at RMCH&RC, she now works with clients internationally & runs two physical clinics (Meerut City, Uttar Pradesh & Ambala Cantt., Haryana) in India, offering compassionate, holistic guidance that honours the interconnectedness of emotional wellbeing, physical health, and lifestyle patterns.
Contact & Credentials
Amrita Singh
Homoeopath, Psychologist & Nutritionist
Dip. CCH (England) | MSc Psychology (England) | MSc Food, Nutrition & Dietetics (India)
MCMA | R. Hom. Int. (Balen’s Insured) | GMBPsS
📧 [email protected]
🌐 https://amritasingh.co.uk/
📍 United Kingdom
Instagram – https://www.instagram.com/clinic_uk_2025/Facebook – https://www.facebook.com/profile.php?id=61582871564526